… separate analyses of relative treatment efficacy within patient subsets can be illustrated as
… B and partition our patients into G mutually exclusive subsets. For each subset we perform a …

… therapy after three patients developed immune thrombocytopenia, one of whom died. During
the suspension, all safety and efficacy assessments proceeded as planned, and patients …

… Since head and neck cancer patients are a heterogeneous group, there may be particular
sites and stages for which adjuvant chemotherapy would be advantageous, and subset …

… Although it is reassuring that the benefits of combination therapy … patient subsets may not
be fully representative of older breast cancer patients in the general population, as patients with …

… trials of therapy for multiple … therapy fails to show any therapeutic effect. The diagnosis,
clinical course, and definitions of the stages of MS are discussed as they relate to trials of therapy. …

… efficacy and safety of 2 doses of cabozantinib in 222 patients … subset of patients who were
naive to antiangiogenic therapy at … for patients who received prior antiangiogenic therapy are …

… Targeted therapies are drugs that, based on their mechanism of action, are designed to …
subsets of patients with specific molecular alterations among the larger population of patients …

… In recent years, enormous effort has been made in the assessment of the prognostic
value of multiple immune cell subsets. Herein, we provide a comprehensive summary of the …

… with HCC, our findings indicate that sorafenib simplifies the process for initiating therapy
and minimises or eliminates some of the clinical parameters that may be contraindications to …

… Results are limited by small patient numbers in some subsets. … of patients who had received
prior curative therapies or TACE … a trend toward improved OS, irrespective of prior therapy. …